These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 28792479)

  • 1. Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.
    Kruspe S; Giangrande PH
    Biomedicines; 2017 Aug; 5(3):. PubMed ID: 28792479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current progress on aptamer-targeted oligonucleotide therapeutics.
    Dassie JP; Giangrande PH
    Ther Deliv; 2013 Dec; 4(12):1527-46. PubMed ID: 24304250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
    Sivakumar P; Kim S; Kang HC; Shim MS
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current progress of RNA aptamer-based therapeutics.
    Zhou J; Bobbin ML; Burnett JC; Rossi JJ
    Front Genet; 2012; 3():234. PubMed ID: 23130020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aptamer-siRNA chimeras for HIV.
    Takahashi M; Burnett JC; Rossi JJ
    Adv Exp Med Biol; 2015; 848():211-34. PubMed ID: 25757623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
    Li X; Zhao Q; Qiu L
    J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in aptamer-mediated targeted delivery system for cancer treatment.
    He S; Du Y; Tao H; Duan H
    Int J Biol Macromol; 2023 May; 238():124173. PubMed ID: 36965552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer-targeted cell-specific RNA interference.
    Zhou J; Rossi JJ
    Silence; 2010 Feb; 1(1):4. PubMed ID: 20226078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aptamer-siRNA chimeras: Promising tools for targeting HER2 signaling in cancer.
    Dhanya CR; Mary AS; Madhavan M
    Chem Biol Drug Des; 2023 May; 101(5):1162-1180. PubMed ID: 36099164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers.
    Hernandez LI; Flenker KS; Hernandez FJ; Klingelhutz AJ; McNamara JO; Giangrande PH
    Pharmaceuticals (Basel); 2013 Mar; 6(3):295-319. PubMed ID: 23894227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Preparation of Aptamer-siRNA Chimeras (AsiCs) for Targeted Cancer Therapy.
    Kruspe S; Giangrande PH
    Methods Mol Biol; 2017; 1632():175-186. PubMed ID: 28730439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs.
    Khanali J; Azangou-Khyavy M; Asaadi Y; Jamalkhah M; Kiani J
    Front Microbiol; 2021; 12():758948. PubMed ID: 34858370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells.
    Esposito CL; Catuogno S; de Franciscis V
    J RNAi Gene Silencing; 2014; 10():500-6. PubMed ID: 25414727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy.
    Aaldering LJ; Tayeb H; Krishnan S; Fletcher S; Wilton SD; Veedu RN
    RNA Biol; 2015; 12(4):412-25. PubMed ID: 25849197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin-Binding Aptamer Chimeras for Improved siRNA Bioavailability.
    Rosch JC; Hoogenboezem EN; Sorets AG; Duvall CL; Lippmann ES
    Cell Mol Bioeng; 2022 Apr; 15(2):161-173. PubMed ID: 35401842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic potential of cell-internalizing aptamers.
    Zhou J; Rossi JJ
    Curr Top Med Chem; 2009; 9(12):1144-57. PubMed ID: 19860714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stick-Based Methods for Aptamer-Mediated siRNA Targeted Delivery.
    Catuogno S; Esposito CL; Giangrande PH
    Methods Mol Biol; 2021; 2282():31-42. PubMed ID: 33928568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.
    Gilboa E; Berezhnoy A; Schrand B
    Cancer Immunol Res; 2015 Nov; 3(11):1195-200. PubMed ID: 26541880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-based therapeutics: current progress and future prospects.
    Burnett JC; Rossi JJ
    Chem Biol; 2012 Jan; 19(1):60-71. PubMed ID: 22284355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligonucleotide aptamers: new tools for targeted cancer therapy.
    Sun H; Zhu X; Lu PY; Rosato RR; Tan W; Zu Y
    Mol Ther Nucleic Acids; 2014 Aug; 3(8):e182. PubMed ID: 25093706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.